Skip to main content
Clinical Trials/NCT01889823
NCT01889823
Completed
Phase 1

Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.

Radboud University Medical Center1 site in 1 country20 target enrollmentJune 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hypoxia
Sponsor
Radboud University Medical Center
Enrollment
20
Locations
1
Primary Endpoint
Hypoxia Inducible Factor 1 alpha in circulating leukocytes
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

It has been shown in in vitro and animal models that hypoxia can have pro-inflammatory effects and hyperoxia can have anti-inflammatory effects. The pro-inflammatory effect could be the result of activation of Hypoxia Inducible Factor, a transcription factor that is known to activate many cell systems aimed at cell survival, including the inflammatory response. The anti-inflammatory effects of hyperoxia could be the annihilation of Hypoxia Inducible Factor, but also a decrease in inflammation due to oxygen toxicity resulting in a decrease in clearance of pathogens. These effects have been sparsely studied in humans. Therefore, we hypothesize that hypoxia results in an increase in Hypoxia Inducible Factor in circulating leukocytes and increases inflammatory reactions, whereas hyperoxia decreases these reactions.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
December 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Peter Pickkers

Prof. dr. P. Pickkers

Radboud University Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 and ≤35 yrs

Exclusion Criteria

  • Use of any medication
  • History, signs or symptoms of cardiovascular disease
  • History of atrial or ventricular arrhythmia
  • (Family) history of myocardial infarction or stroke under the age of 65 years
  • Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block
  • Hypertension (defined as RR systolic \> 160 or RR diastolic \> 90 mmHg)
  • Hypotension (defined as RR systolic \< 100 or RR diastolic \< 50 mmHg)
  • Renal impairment (defined as plasma creatinine \>120 μmol/l)
  • Liver enzyme abnormalities alkaline phosphatase\>230 U/L and/or ALT\>90 U/L
  • Medical history of any obvious disease associated with immune deficiency

Outcomes

Primary Outcomes

Hypoxia Inducible Factor 1 alpha in circulating leukocytes

Time Frame: 24 hours

Hypoxia Inducible Factor 1 alpha in circulating neutrophils, lymphocytes and monocytes as measured with flow cytometry

Secondary Outcomes

  • ventilatory response(24 hours)
  • adenosine metabolism(24 hours)
  • Hepcidin and iron parameters(24 hours)
  • subjective symptoms(24 hours)
  • high sensitive troponin(24 hours)
  • oxygen saturation and PaO2(24 hours)
  • iFABP(24 hours)
  • Brain specific proteins(24 hours)
  • endocan(24 hours)
  • Phagocytic function of circulating leukocytes(24 hours)
  • cognitive function(24 hours)
  • Neutrophil function(24 hours)
  • Reactive Oxygen Species in circulating leukocytes(24 hours)
  • circulating cytokines (including but not limited to IL-6, IL-10, IL-1RA)(24 hours)
  • body temperature(24 hours)
  • VEGF(24 hours)
  • cytokine production after ex vivo stimulation of leukocytes(24 hours)
  • catecholamines(24 hours)
  • adrenomedullin(24 hours)
  • Hemodynamic parameters(24 hours)
  • alkaline phosphatase(24 hours)
  • EPO(24 hours)
  • Hypoxia Inducible Factor mRNA and anti Hypoxia Inducible Factor mRNA in circulating leukocytes(24 hours)
  • Heart rate variability(24 hours)

Study Sites (1)

Loading locations...

Similar Trials